Sign In
Buy SNDX
$19.05
-0.430 (-2.21%)
At Close: Jul 31, 2026
Syndax Announces Participation at Three Upcoming Investor Conferences
07:00am, Thursday, 02'nd Sep 2021
WALTHAM, Mass., Sept. 2, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipelin
Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q2 2021 Results - Earnings Call Transcript
10:49pm, Monday, 09'th Aug 2021
Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q2 2021 Results - Earnings Call Transcript
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Misses Revenue Estimates
07:13pm, Monday, 09'th Aug 2021
Syndax (SNDX) delivered earnings and revenue surprises of 40.54% and -24.20%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
SNDX-5613 Granted FDA Fast Track Designation for the Treatment of Relapsed/Refractory Acute Leukemias
07:00am, Monday, 28'th Jun 2021
WALTHAM, Mass., June 28, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipelin
Syndax Announces Participation in Goldman Sachs 42nd Annual Global Healthcare Conference
07:00am, Thursday, 03'rd Jun 2021
WALTHAM, Mass., June 3, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipelin
Syndax Announces Participation in Cowen 2nd Annual Virtual Oncology Innovation Summit
07:00am, Thursday, 13'th May 2021
WALTHAM, Mass., May 13, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline
Syndax Pharma Updates On Interim Phase 1 Data From SNDX-5613 Leukemia Trial
07:51am, Wednesday, 12'th May 2021
Syndax Pharmaceuticals Inc (NASDAQ: SNDX), in its Q1 earnings, also announced new data from the ongoing Phase 1 dose-escalation portion of the Phase 1/2 AUGMENT-101 trial evaluating SNDX-5613 in
Syndax Pharmaceuticals, Inc. (SNDX) CEO Dr. Briggs Morrison on Q1 2021 Results - Earnings Call Transcript
10:31pm, Tuesday, 11'th May 2021
Syndax Pharmaceuticals, Inc. (SNDX) CEO Dr. Briggs Morrison on Q1 2021 Results - Earnings Call Transcript
Recap: Syndax Pharmaceuticals Q1 Earnings
05:04pm, Tuesday, 11'th May 2021
Shares of Syndax Pharmaceuticals (NASDAQ:SNDX) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 3.57% year over year to ($0.54), which
Syndax Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical and Business Update
04:01pm, Tuesday, 11'th May 2021
WALTHAM, Mass., May 11, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipelin
Syndax to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11, 2021
07:00am, Tuesday, 04'th May 2021
WALTHAM, Mass., May 4, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline
Syndax (SNDX) Moves 10.7% Higher: Will This Strength Last?
09:46am, Thursday, 22'nd Apr 2021
Syndax (SNDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Why Syndax Pharmaceuticals Stock Is Sinking Today
04:18pm, Tuesday, 20'th Apr 2021
The company announced results from an early-stage clinical study.
Why Crispr, KalVista And Syndax Are Moving Today
09:18am, Tuesday, 20'th Apr 2021
CRISPR Therapeutics AG (NASDAQ: CRSP), Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) and KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) were among the early movers in the biopharma space Tuesday. CRISPR
WALTHAM, Mass., April 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeli
